69
Views
9
CrossRef citations to date
0
Altmetric
Original Research

Not all partial dopamine D2 receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse

, &
Pages 589-603 | Published online: 06 Sep 2010

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Hugo Geerts, Athan Spiros & Patrick Roberts. (2017) Phosphodiesterase 10 inhibitors in clinical development for CNS disorders. Expert Review of Neurotherapeutics 17:6, pages 553-560.
Read now
Athan Spiros & Hugo Geerts. (2012) A quantitative way to estimate clinical off-target effects for human membrane brain targets in CNS research and development. Journal of Experimental Pharmacology 4, pages 53-61.
Read now

Articles from other publishers (7)

Rachel Rose, Emma Mitchell, Piet Van Der Graaf, Daisuke Takaichi, Jun Hosogi & Hugo Geerts. (2022) A quantitative systems pharmacology model for simulating OFF-Time in augmentation trials for Parkinson’s disease: application to preladenant. Journal of Pharmacokinetics and Pharmacodynamics 49:6, pages 593-606.
Crossref
Patrick D. Roberts & James Conour. (2022) Mechanistic modeling as an explanatory tool for clinical treatment of chronic catatonia. Frontiers in Pharmacology 13.
Crossref
Athan Spiros & Hugo Geerts. (2021) Toward Predicting Impact of Common Genetic Variants on Schizophrenia Clinical Responses With Antipsychotics: A Quantitative System Pharmacology Study. Frontiers in Neuroscience 15.
Crossref
Hugo Geerts & James E. Barrett. (2019) Neuronal Circuit-Based Computer Modeling as a Phenotypic Strategy for CNS R&D. Frontiers in Neuroscience 13.
Crossref
Patrick Roberts, Athan Spiros & Hugo Geerts. (2016) A Humanized Clinically Calibrated Quantitative Systems Pharmacology Model for Hypokinetic Motor Symptoms in Parkinson’s Disease. Frontiers in Pharmacology 7.
Crossref
Hugo Geerts, Patrick Roberts & Athan Spiros. (2015) Assessing the synergy between cholinomimetics and memantine as augmentation therapy in cognitive impairment in schizophrenia. A virtual human patient trial using quantitative systems pharmacology. Frontiers in Pharmacology 6.
Crossref
Athan Spiros, Patrick Roberts & Hugo Geerts. (2014) A computer-based quantitative systems pharmacology model of negative symptoms in schizophrenia: exploring glycine modulation of excitation-inhibition balance. Frontiers in Pharmacology 5.
Crossref